In a comprehensive review of the on-going or completed clinical trials for HS, Maarouf et al. [27] identified the following treatment targets—TNFα inhibition, the use of IL-1R antagonists, molecules targeting the IL-17 and IL-12/23 signalling pathways and complementary 5a inhibitors. This evidence concerns the gene TNF and histiocytic sarcoma.